Reference

Diagnostic compositions for assessment of pancreatic insufficiency

Diagnostic compositions for assessment of pancreatic insufficiency. Jollifee, Stephen Ronald; Weaver, Lawrence Trevelyan (Charwell Pharmaceuticals Ltd., UK). PCT Int. Appl. WO 9201478 A1 6 Feb 1992, 22 pp. DESIGNATED STATES: W: AU, CA, JP, US; RW: AT, BE, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IT, LU, ML, MR, NL, SE, SN, TD. (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K049-00. APPLICATION: WO 91-GB1190 18 Jul 1991. PRIORITY: GB 90-15851 19 Jul 1990; GB 91-14042 27 Jun 1991. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1, 8 A diagnostic compn. for detecting pancreatic insufficiency comprises a fatty acid ester of fluorescein (I) and a nontoxic saccharide, such as mannitol (II) which is resistant to breakdown within the stomach and does not take part in any active transport system across the intestinal mucosa. I and II are excreted in the urine and the ratio of recovered I:II allows for the detection of pancreatic insufficiency without the need for control expts. An oral emulsion contained I dilaurate (III) 0.87, Miglyol 812 (coconut oil triglyceride) 12.50, Lipoid S05 (soya bean lecithin) 2.5, and water 84.13%. Patients with cystic fibrosis were given capsules contg.There are some commonly used reagents with their cas registry numbers 7308-90-9 and 4618-18-2 in this article. III 0.5, and II 25 mmols and urine was collected for 10 h and urinary III and II were measured. The ratio of III to II was 3.1 as compared to 57.3 for healthy controls. .

Two indirect tests of exocrine pancreatic function evaluated

Two indirect tests of exocrine pancreatic function evaluated. Scharpe, Simon; Iliano, Luc (Dep. Clin. Biochem., Univ. Antwerp, Wilrijk 2610, Belg.). Clin. Chem. (Winston-Salem, N. C.), 33(1), 5-12 (English) 1987. CODEN: CLCHAU. ISSN: 0009-9147. DOCUMENT TYPE: Journal; General Review CA Section: 9 (Biochemical Methods) Section cross-reference(s): 14 A review with 86 refs. which describes and evaluates 2 frequently used indirect methods for assessing exocrine pancreatic function: the N-benzoly-L-tyrosyl-p-aminobenzoic acid test (NBT-PABA) and the pancreolauryl (fluorescein dilaurate) test.There are some commonly used reagents with their cas registry numbers 7308-90-9 and 37106-97-1 in this article. Both tests can be used in the diagnosis and monitoring of cystic fibrosis, chronic pancreatitis, and pancreatic carcinoma, and in monitoring pancreatic enzyme replacement therapy to det. the appropriate dose. In comparison with the NBT-PABA procedure, the pancreolauryl test seems to have better specificity and sensitivity, undergoes almost no interference from other drugs or serum compds., requires no complex hydrolytic conditions, and is independent of renal function. .